| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
| Neuroscience Is Taking the Spotlight at Xconomy’s Bay Area Xchange | Frank Vinluan | 11/11/19 | San Francisco |
| The Placebo Effect Is Hobbling New Psychiatric Drugs. What Can Stop It? | Alex Lash | 10/10/19 | National |
| Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More | Ben Fidler | 06/14/19 | National |
| Can AI Tools, $76M Lead BlackThorn to Targeted Psych Drugs? | Ben Fidler | 06/13/19 | San Francisco |
| Mindstrong Adds $15M for Tech That Predicts Mental Health Changes | David Holley | 06/14/18 | San Francisco |
| Former Gates Investor, Advisor Unveil $200M Biomatics Health Fund | Alex Lash | 03/15/17 | Seattle |
| BlackThorn Therapeutics Obtains $14,000,000 Series A Funding | VentureDeal | 01/06/17 | San Francisco |
| Bio Roundup: Jenkins Gets Mad, Bernie Gets His Pen, CRISPR IPO & J-Lo | Alex Lash | 10/21/16 | National |
| BlackThorn Therapeutics Garners $40,000,000 Series A Round | VentureDeal | 10/21/16 | San Francisco |
| BlackThorn Emerges With $40M, New Weapons Against Neuro Disorders | Ben Fidler | 10/20/16 | San Francisco |
| West Coast Bio Roundup: Shkreli, BlackThorn, Unhappy Holiday Layoffs | Alex Lash | 12/24/15 | San Francisco |
| Amid Neuroscience Renaissance, BlackThorn Quietly Builds a Business | Alex Lash | 12/23/15 | San Francisco |
